Home › 4 Reasons To Keep An Eye On Top Biotech Celgene
 

Keywords :   


4 Reasons To Keep An Eye On Top Biotech Celgene

2015-08-22 16:57:54| Biotech - Topix.net

While Celgene has pulled back with the market, growth prospects for the IBD Big Cap 20 biotech leader remain healthy. Boosted by its buyout of Receptos and investment in Juno Therapeutics, the maker of cancer therapy Revlimid projects revenue growth to more than double to $21 billion in 2020.

Tags: top reasons eye biotech

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
29.09Eastern North Pacific Tropical Weather Outlook
28.09Hurricane Isaac Graphics
28.09Hurricane Isaac Forecast Discussion Number 12
28.09Tropical Storm Joyce Graphics
28.09Hurricane Isaac Wind Speed Probabilities Number 12
28.09Hurricane Isaac Forecast Advisory Number 12
28.09Hurricane Isaac Public Advisory Number 12
28.09Summary for Hurricane Isaac (AT5/AL102024)
More »